AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

Camrelizumab plus sorafenib or apatinib achieved long-term survival in a patient with hepatocellular carcinoma and an Eastern Cooperative Oncology Group performance status of 3: a case report. (PubMed, J Gastrointest Oncol) - "Treatment adherence was complicated by financial interruptions but resumed with a combination of apatinib plus camrelizumab. This case may provide preliminary support for the potential use of targeted therapy combined with immune checkpoint inhibitors in patients with HCC and an ECOG performance status of 3."

IO biomarker • Journal • Cardiovascular • Hematological Disorders • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor • Thrombosis • AFP

ICT-HCC: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Nanjing Tianyinshan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Hepatocellular Cancer • Oncology • Solid Tumor

Prolonged Progression-Free Survival in a Patient with Highly Pretreated Recurrent Ovarian Cancer after Developing Multisystem Immune-Related Adverse Events: A Case Report and Literature Review. (PubMed, Case Rep Oncol) - "Between 2013 and 2021, she underwent palliative chemotherapy comprising paclitaxel liposomes, cisplatin/nedaplatin, S-1/raltitrexed, irinotecan, doxorubicin, vinorebine, toripalimab, apatinib, gemcitabine, oxaliplatin, and capecitabine, as well as two debulking surgeries. From November 2021, she received six cycles of tislelizumab (a PD-1 inhibitor), paclitaxel (albumin-bound), and carboplatin, to which a partial response was observed according to the Response Evaluation Criteria in Solid Tumors. From May 2022, the patient was switched to maintenance therapy with tislelizumab plus olaparib...We report a case involving a patient with highly pretreated recurrent ovarian cancer who exhibited prolonged PFS after developing three irAEs. The distinctly prolonged PFS observed, along with the reviewed literature, suggests that irAEs may be correlated with improved survival in ovarian cancer."

Adverse events • IO biomarker • Journal • Tumor mutational burden • Endocrine Disorders • Gynecology • Microsatellite Instability • Nephrology • Obstetrics • Oncology • Ovarian Cancer • Pneumonia • Renal Disease • Solid Tumor • MSI • TMB

Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer. (PubMed, Int J Cancer) - "We explored the feasibility and efficacy of sintilimab plus two-drug chemotherapy (S-1 plus nab-paclitaxel) and apatinib as conversion therapy in patients with stage IV gastric cancer in China...The safety profile was manageable. Sintilimab plus chemotherapy and apatinib followed by conversional resection may be a new feasible and safe option for initially unresectable gastric cancer, potentially leading to long-term survival or even cure."

Journal • Gastric Cancer • Oncology • Solid Tumor

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma. (PubMed, Front Immunol) - "Sintilimab and camrelizumab, both plus targeted agents, have equal clinical effectiveness and incidences of AEs. The effectiveness of sintilimab-lenvatinib and camrelizumab-apatinib are similar in first-line treatment of advanced HCC, despite a slight superiority in sintilimab-lenvatinib is observed."

Clinical • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Updated Network Meta-Analysis of First-Line Systemic Treatments for Advanced HCC: Consistent Role of TACE. (PubMed, Liver Cancer) - "Transarterial chemoembolization (TACE) combined with lenvatinib provided the greatest improvement in OS over sorafenib, with a hazard ratio of 0.41 (95% confidence interval, 0.30-0.58), followed by sintilimab + IBI305 (0.57; 0.43-0.75), camrelizumab + rivoceranib (0.62; 0.48-0.80), atezolizumab + bevacizumab (0.66; 0.51-0.85), lenvatinib + pembrolizumab (0.77; 0.62-0.97), and tremelimumab + durvalumab (0.78; 0.64-0.95). For advanced HCC, our first-line analysis consistently scored TACE + lenvatinib the best for survival outcomes, followed by various immunotherapy-based combinations. However, the superior efficacy of TACE + lenvatinib should be interpreted with consideration of its derivation from a region with high hepatitis B virus prevalence."

Journal • Retrospective data • Review • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Liver Cancer • Oncology • Solid Tumor

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: Peking Union Medical College Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma

A momentous progress update: epidermal growth factor receptor inhibitors as viable agents for combating cancer. (PubMed, RSC Med Chem) - "However, clinically used EGFRs such as apatinib, selumetinib, gefitinib, vandetanib, and erlotinib are not selective, thereby resulting in troublesome side effects. Preclinical, clinical, structure-activity relationships (SAR) with mechanism-based and in silico research, and other relevant data are compiled to offer directions for the scientific discovery of novel EGFR inhibitors with conceivable uses in therapy. The research trajectory of this entire field will provide incessant opportunities for the discovery of novel drug molecules with improved efficacy and selectivity."

Journal • Review • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • EGFR • ERBB3 • ERBB4 • HER-2

Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310) (ESMO-GI 2025) - P3 | "These results suggest meaningful clinical benefit of cam + rivo as first-line therapy for uHCC compared to sor regardless of baseline AFP level or etiology."

Clinical • Clinical data • Hepatocellular Cancer • Oncology • Solid Tumor • AFP • FLT1

Efficacy and Safety of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study (ASTRO 2025) - No abstract available

Clinical • Combination therapy • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB-TACE combined with lenvatinib and camrelizumab. (PubMed, Front Immunol) - "Initially, he received apatinib in combination with camrelizumab; however, due to intolerance to apatinib's side effects, the regimen was adjusted to lenvatinib and camrelizumab. The combination of DEB-TACE, lenvatinib, and camrelizumab demonstrated efficacy in a patient with advanced HCC and lung metastases. These findings suggest that integrating MKIs and ICIs may represent a potential treatment approach for select advanced HCC cases, warranting further validation in larger studies."

Journal • Fibrosis • Gastroenterology • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • Solid Tumor

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=25 | Terminated | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=230 ➔ 25 | Unknown status ➔ Terminated; The sponsor's R&D strategy is adjusted.

Enrollment change • IO biomarker • Trial termination • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Cholesterol confers resistance to Apatinib-mediated ferroptosis in gastric cancer. (PubMed, Cell Biosci) - No abstract available

Journal • Gastric Cancer • Oncology • Solid Tumor

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping: Chemotherapy, Immunotherapy, or Targeted Therapy?-A Retrospective Analysis. (PubMed, Ann Surg Oncol) - "Our analysis has revealed that, for neoadjuvant therapy in AGC, the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib."

IO biomarker • Journal • Retrospective data • Gastric Cancer • Oncology • Solid Tumor

Research letter: immune checkpoint inhibitors against thyroid cancer. (PubMed, Int J Surg) - "The study presents some valuable insights regarding the present state and future perspectives of clinical trials on thyroid cancer."

Checkpoint inhibition • IO biomarker • Journal • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • BRAF

Phase II study of transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced perihilar cholangiocarcinoma. (PubMed, Sci Rep) - "A comprehensive treatment plan involving TACE combined with targeted therapy was implemented for the patients with pathologically diagnosed advanced PCC, where TACE was performed every 4-6 weeks to deliver albumin paclitaxel and gemcitabine for a maximum of six times. Among the most common AEs were bone marrow suppression and hand-foot syndrome, while no patient had Grade 4 AE. Comprehensive treatment combining TACE with apatinib for advanced PCC had favorable therapeutic effects, and no major safety issue was observed in the patients enrolled."

Journal • P2 data • Biliary Cancer • Cholangiocarcinoma • Dermatology • Oncology • Solid Tumor

MAPPING THE DIVERSITY OF IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER: TREATMENTS, OUTCOMES, AND SIDE-EFFECTS WITH IMMUNE CHECKPOINT INHIBITORS (MASCC-ISOO 2025) - "Results Treatments included monotherapies with PD-1 inhibitors (e.g., Pembrolizumab, Nivolumab), PD-L1 inhibitors (e.g., Atezolizumab, Durvalumab), and combination therapies with chemotherapy (e.g., Nab-paclitaxel, carboplatin), targeted therapies (e.g., Apatinib, Olaparib), and radiotherapy (e.g., stereotactic body radiotherapy). While immune-related AEs were common, they were largely manageable. Further research into novel combinations and biomarker validation is essential to advance precision immunotherapy for TNBC."

Adverse events • Checkpoint inhibition • IO biomarker • Tumor mutational burden • Breast Cancer • Fatigue • Neutropenia • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • TMB

The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study. (PubMed, Front Oncol) - "Safety profiles were comparable between groups, with no significant increase in severe adverse events with combination therapy. Apatinib combined with ICIs demonstrated improved survival outcomes compared to apatinib monotherapy in AGC, particularly for patients with liver metastasis, without increasing severe toxicity."

Checkpoint inhibition • Journal • Real-world evidence • Gastric Cancer • Oncology • Solid Tumor

CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A MULTICENTER PHASE II STudy (ICML 2025) - "The combination of camrelizumab, low-dose apatinib, and pegaspargase followed by radiotherapy demonstrated significant efficacy and manageable toxicity in newly diagnosed stage I/II NK/TCL. The promising CR rates and favorable safety profile suggest that this regimen could serve as a viable alternative to conventional chemoradiotherapy for this patient population."

Clinical • P2 data • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy. (PubMed, J Hepatocell Carcinoma) - "All adverse events were manageable, and no treatment-related deaths occurred. HAIC combined with apatinib/camrelizumab is effective and safe in the treatment of recurrent HCC after hepatectomy, which may be a promising treatment for recurrent HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Neoadjuvant Treatment of Ovarian Cancer With Fluazoparib in Combination With Apatinib (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

New P2 trial • Oncology • Ovarian Cancer • Solid Tumor

Significance of hemoglobin and hematocrit changes in predicting patient survival and efficacy of neoadjuvant chemotherapy for advanced gastric cancer. (PubMed, World J Gastrointest Oncol) - "Hematocrit < 33% and hemoglobin < 107 g/L are risk factors for chemotherapy failure in patients with advanced gastric cancer. They are associated with poorer prognosis and reduced 3-year survival rates."

Journal • Gastric Cancer • Hematological Disorders • Oncology • Solid Tumor

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=43 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xiamen University

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Case report of complete remission in two patients with Barcelona stage C hepatocellular carcinoma treated with apatinib combined with camrelizumab. (PubMed, Am J Transl Res) - "This report presents two cases of Barcelona Clinic Liver Cancer (BCLC) stage C HCC that achieved complete remission following treatment with apatinib plus camrelizumab. According to the Response Evaluation Criteria in Solid Tumors, both patients achieved complete response, allowing for drug discontinuation."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Ruijin Hospital

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor